Table 4.
Summary of meta-analyses focused on MRI and PET/CT for the assessment of breast cancer response to NAC.
| Study | Search date | No. | Modality | PSEN (95% CI) | PSPE (95% CI) | DOR (95% CI) | AUC (95% CI) |
|---|---|---|---|---|---|---|---|
| Michae l7 | to 2011 | 44 | MRI | 0.92(0.85–0.97) | 0.60(0.39–0.96) | 17.89(11.45, 27.95) | 0.88(NR) |
| Mghanga8 | 2000–2012 | 15 | PET/CT | 0.81(0.76, 0.85) | 0.79(0.74, 0.83) | NR | 0.88(0.86–0.90) |
| Liu24 | 1992–2015 | 6 | MRI | 0.65(0.45, 0.80) | 0.88(0.75, 0.95) | NR | 0.84(0.80, 0.87) |
| 6 | PET/CT | 0.86(0.76, 0.93) | 0.72(0.49, 0.87) | NR | 0.88(0.85, 0.91) | ||
| Our | 2000–2016 | 11 | MRI | 0.79(0.76, 0.87) | 0.82(0.72, 0.89) | 16.43(10.05, 26.87) | 0.87(0.84, 0.90) |
| 11 | PET/CT | 0.87(0.71, 0.95) | 0.85(0.70, 0.93) | 37.25(17.01, 81.62) | 0.93(0.90, 0.95) |
PSEN = pooled sensitivities; PSPE = pooled specificities; DOR = diagnostic odds ratio; NR = not reported.